Pacific Bio (PACB) Tops Q1 EPS by 1c

Pacific Bio (NASDAQ: PACB) reported Q1 EPS of ($0.45), $0.01 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $29 million versus the consensus estimate of $25.58 million.

“PacBio is off to a great start in 2021 as we achieved record revenue in the first quarter that exceeded our expectations,” said Christian Henry, President and Chief Executive Officer. “We installed a record number of Sequel II Systems and recorded our fourth straight quarter of sequential growth. In the first quarter, we made excellent progress on our strategic initiatives, and we remain in the early stages of the impact that PacBio sequencing can have on human health.”

For earnings history and earnings-related data on Pacific Bio (PACB) click here.

You May Also Be Interested In

• BMO Capital Upgrades Casey's General Stores (CASY) to Outperform, 'Opportunity Knocks'
• RBC Capital Upgrades Central Asia Metals plc (CAML:LN) to Sector Perform
• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story